Establishment of reference values of α-tocopherol in plasma, red blood cells and adipose tissue in healthy children to improve the management of chylomicron retention disease, a rare genetic hypocholesterolemia by unknown
RESEARCH Open Access
Establishment of reference values of
α-tocopherol in plasma, red blood cells
and adipose tissue in healthy children to
improve the management of chylomicron
retention disease, a rare genetic
hypocholesterolemia
Charlotte Cuerq1,2, Lioara Restier3, Jocelyne Drai1,2, Emilie Blond1,2, Adeline Roux4, Sybil Charriere2,5,
Marie-Caroline Michalski2, Mathilde Di Filippo2,6, Emile Levy7,8, Alain Lachaux2,3 and Noël Peretti2,3*
Abstract
Background: Chylomicron retention disease (CMRD), a rare genetic hypocholesterolemia, results in
neuro-ophtalmologic damages, which can be prevented by high doses of vitamin E during infancy.
In these patients, plasma vitamin E concentration is significantly reduced due to defects of chylomicron
secretion. Vitamin E in adipose tissue (AT) and red blood cells (RBC) have been proposed as potential
relevant biomarkers of vitamin E status but no reference values in children are available. The objectives
were (i) to establish age-reference intervals in healthy children for α-tocopherol in plasma, red blood cells
(RBC) and adipose tissue (AT) and (ii) to determine the variations of α-tocopherol in patients with CMRD
after oral treatment with vitamin E.
Methods: This prospective study included 166 healthy children (1 month - 18 years) and 4 patients with
CMRD. Blood and AT were collected in healthy children during a scheduled surgery and in patients before
and after a 4-month treatment with α-tocopherol acetate.
Results: The reference ranges for α-tocopherol were 11.9 - 30 μmol/L in plasma, 2.0 - 7.8 μmol/L packed
cells in RBC and 60 - 573 nmol/g in AT. α-tocopherol levels in plasma correlated with those of RBC
(r = 0.31; p < 0.01).
In patients with CMRD after 4 months treatment, α-tocopherol concentrations remained less than 70 % of
the control values in plasma, increased by 180 % to reach normal values in RBC, and remained stable in
the normal range in AT.
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Conclusion: This study establishes pediatric reference intervals for α-tocopherol in plasma, RBC and AT.
These values will be beneficial in assessing accurate α-tocopherol status in children and to optimize the
monitoring of rare diseases such as CMRD. Our data suggest that RBC α-tocopherol, appears as a relevant
biomarker to appreciate the effectiveness of treatment with α-tocopherol in patients with a rare primary
hypocholesterolemia. The biopsy of AT could be used at diagnosis to assess the severity of the vitamin E
deficiency and periodically after a long duration of vitamin E therapy to assess whether the treatment is
effective, based on reference intervals defined in this study.
Keywords: α-tocopherol, Vitamin E, Red blood cells, Adipose tissue, Primary hypocholesterolemia, Anderson’s
disease, Chylomicron retention disease, Reference interval
Background
Vitamin E is known to be an essential micronutrient for
promoting the development and maintaining the health
due to its antioxidant and non-antioxidant biological
activities [1, 2]. As a chain-reaction breaking antioxidant,
vitamin E prevents the propagation of lipid-peroxidation,
especially of polyunsattured fatty acids of cell membranes
and low-density lipoproteins (LDL) from oxidation by free
radicals. It also modulates genes expression and enzymatic
activities and inhibits cell proliferation, platelet aggrega-
tion and monocyte adhesion [3]. Chylomicron Retention
Disease (CMRD) (OMIM#246700), also called Anderson’s
Disease (OMIM#607689), is a rare genetic disease due
to mutations in the SARA2 gene coding for the Sar1b
GTPase protein [4]. It is among the genetic syndromes
associated with congenital lipid malabsorption such as
abetalipoproteinemia (ABL) and familial hypobetalipo-
proteinemia, a heterogeneous group of disorders charac-
terised by a decrease of LDL-cholesterol (LDLc) and
apolipoprotein B (Apo B) [5]. The clinical expression of
these diseases is an important lipid malabsorption with
severe malnutrition in the neonatal period along with
ataxic neuropathy and ophthalmologic impairments during
the second decade of life due to α-tocopherol deficiency
[6]. In these patients, plasma vitamin E concentration is
significantly reduced due to defects of chylomicron assem-
bly and secretion, which are obligatory for its absorption.
Similarly, the lack of low-density lipoproteins (LDL)
and very-low-density lipoproteins (VLDL), necessary for its
transport into the blood, are additional complicating
factors. As plasma tocopherol is a poor indicator of body
vitamin E stores in familial hypocholesterolemia, we needed
an alternative measure less dependent on blood lipids for
their monitoring. It has been estimated that about 90 % of
the total body content of tocopherol is found in adipose
tissue [7]. Therefore, vitamin E in adipose tissue (AT) has
been proposed as a potential indicator of long-term intake
of vitamin E. Studies performed in ABL patients have
shown that treatment with large doses (10 g/d) of vitamin
E prevented complications and increased tocopherol con-
centration in AT to normal levels [8, 9]. However, while
some data on the concentration of vitamin E in AT are
available in the literature pertinent to adults [10–12], there
are no reference values for children. The age factor may
influence the level of the micronutrients in healthy people
as is the case for vitamin A [13, 14]. In addition, the AT
biopsy remains an invasive procedure difficult to perform
during the systematic management of children with
primary hypocholesterolemia. An easier alternative could
be to measure vitamin E levels in red blood cells (RBC)
but the scientific literature is deficient in reference values
for vitamin E levels in RBC in American and European
children.
The objectives of our study were, therefore, first to
establish reference intervals for α-tocopherol in plasma,
RBC and AT in healthy children aged 1 month to 18 years,
and second to determine whether the measurement of
α-tocopherol in RBC could be an alternative to the AT





Eligible subjects were healthy children aged 1 month to
18 years with a scheduled surgery. Children were recruited
from the digestive or orthopedic surgical units of a univer-
sity pediatric hospital. Exclusion criteria for the study were
dyslipidemia, malnutrition, renal or hepatic diseases and
vitamin E treatment. The study protocol was approved by
the hospital ethics committee. The parents (and children
when they were old enough) signed a non-opposition form.
Patients were enrolled without regardless of race, gender or
ethnic background. Children were divided into three age
groups: 1 month to 2 years, 2 - 11 years, 12 - 18 years based
on slightly modified international recommendations [15].
They were recruited from January 2009 to October 2011.
CMRD patients
Four patients with CMRD (3 girls and 1 boy, from 15
to 21 years, mean age = 19 years) were also included
in the present study. All patients have been treated
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for several years by 50 mg/kg/d of α-tocopherol acetate. To
evaluate the variation of α-tocopherol status, patients had a
2 month-washout period and they were then treated for
4 months with 50 mg/kg/d of tocopherol acetate. Alpha-
tocopherol concentrations were measured in plasma, RBC
and AT at the beginning and the end of the 4 months
of treatment. The study protocol was approved by the
hospital ethics committee and by the National Agency for
Medicines and Health Products and complied with the
Helsinki Declaration. If the child was a minor, a detailed
informed consent form was signed by the child and his
parents. When they were major, the children signed their
own consent before their participation in the study.
Sample collection and processing
Healthy controls
At the time of peripheral venipuncture, 6 ml of blood
(3 mL sample in lithium heparin and 3 mL sample in
additive clot activator tubes) were collected for determi-
nation of lipid profile and vitamin E in plasma and RBC.
The tubes were processed within 4 hours after collection.
At the beginning of surgery, three samples of appro-
ximately 100 mg of subcutaneous AT were collected for
determination of vitamin E concentration in AT. Immedi-
ately, AT samples were washed with 1 mL saline solution,
kept in a plastic adaptor, and frozen in liquid nitrogen and
then stored < -70 °C.
CMRD patients
Before the beginning and at the end of the 4 months
treatment with α-tocopherol acetate, 6 ml of blood were
collected for determining the lipid profile and vitamin
E concentrations in plasma and in RBC. After local
anesthesia, two samples of approximately 50 mg of
abdominal subcutaneous AT were collected by needle
for determination of vitamin E in AT. Samples were
processed as described for controls.
High pressure liquid chromatography (HPLC) analysis of
vitamin E
Plasma, erythrocytes and adipose tissue samples for deter-
mination of α-tocopherol concentrations were analyzed by
HPLC using a Summit Dionex system (Thermo Fisher
Scientific) and Chromeleon software (version 6.80, Thermo
Fisher Scientific). Two levels of internal quality control
were assayed at the beginning of each run. Furthermore,
the laboratory participated regularly in external quality-
assurance programs allowing monitoring of the measure-
ment methods (bias and total error).
Plasma assay
Briefly, after precipitation of plasma proteins by ethanol,
α-tocopherol was extracted into hexane, evaporated under
nitrogen and the dried residue was dissolved in methanol/
ethanol (85/15, v/v).
The eluate was analyzed by HPLC at 292 nm. Sepa-
ration was carried out on an Adsorbosphere HS C18
3 mm (Interchim) held at 37 °C, using a gradient elution
system starting with 100 % methanol-acetonitrile (40/60,
v/v) and ending with a 100 % mixture of methanol-
acetonitrile-dichloromethane (46/30/24, v/v) as described
by Steghens et al [16]. Tocol was used as internal standard
for measurement of vitamin E concentration to correct
losses during liquid/liquid extraction. The intra-assay
coefficients of variation (CV) for α-tocopherol in plasma
were 2.4 and 1.1 % at respectively 17 and 40 μmol/L. The
inter-assay CVs were respectively 3.9 % and 4 % at the
same levels of concentration.
Erythrocytes assay
Erythrocytes were prepared for tocopherol analysis as
previously described [17]. In brief, erythrocytes were
washed 3 times in saline solution (9 g/L NaCl) containing
pyrogallol (10 g/L) and resuspended in this solution to
give a hematocrit of 50 % and 1 mL aliquots of washed
erythrocytes were stored at < -70 °C until analysis. Alpha-
tocopherol was analysed as described above. The intra-
assay CV was 4.1 % at 5.3 μmol/L packed cells.
Adipose tissue assay
AT samples were removed from the connector, cut into
smaller pieces, weighed (32.5 mg on average), transferred to
a ground glass tissue grinder containing ethanol and an
internal standard (Tissue Grind Comp Sz 20 Kontes
Kimble-Chase LLC) and chilled on ice. The AT was ground
and produced a uniform homogenate. The homogenate
was transferred to a 7 ml glass tube and α-tocopherol was
extracted by hexane as described above. The intra-assay
CV was at 10.1 % at 460 nmol of α-tocopherol per gramme
of adipose tissue.
Measurement of serum lipids concentration
Total cholesterol, triglycerides and HDL-cholesterol were
measured by routine laboratory procedures using an
automated analyzer (Architect, Abbott Diagnostic). The
inter-assay coefficient of variation was less than 3 % over
the sample concentration range for these analytes. LDL-
cholesterol was calculated using the Friedwald formula.
Data analysis
The characteristics of healthy children and patients were
reported using descriptive statistics (e.g. mean, standard
deviation) for each age group and for all children. Refe-
rence intervals were established according to the Clinical
and Laboratory Standards Institute (CLSI) and the Inter-
national Federation of Clinical Chemistry (IFCC) guide-
lines on defining, establishing, and verifying reference
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(C28-A3) [18, 19]. Results were reviewed to detect outliers
using the Tukey’s test prior to estimating reference inter-
vals. Since the number of sample by age was less than the
recommended 120, the non parametric percentile method
was used to estimate reference intervals. Spearman’s rank
correlations coefficients were calculated between AT, RBC
plasma α-tocopherol concentration and cholesterol. Two-
way analysis of variance (ANOVA) were performed to
assess the influence of age and gender on α-tocopherol.
Analyses were performed using SAS version 9.2 (SAS In-
stitute) and MedCalc version 12.7.0.0 (MedCalc software).
Results
Healthy controls
Of 402 eligible individuals, 234 (58 %) declined participa-
tion, mainly because of parental concern and 2 cancelled
their appointment. Finally, 166 (73 females, 43 %) were
included in the analysis. The flowchart for the healthy
children is represented in Fig. 1. The main indications for
surgery were a cryptorchidism (29 %) or a hernia repair
(majority were inguinal or umbilical hernias) (27 %). The
other interventions were orthopedic (19 %), urology and
nephrology interventions (13 %) or miscellaneous (12 %).
For the 166 subjects enrolled, the data were available: i)
from 160 subjects for plasma tocopherol, ii) from 99
subjects for RBC tocopherol and iii) from 145 subjects for
AT tocopherol for various reasons (difficulties in AT
biopsy and venipuncture, or no valid analyses due to
logistical and storage problems). Results were reviewed to
detect outliers using Tukey’s test prior to analysing data, 4
outliers were excluded for plasma and RBC tocopherol
analysis and 1 outlier was excluded for AT tocopherol
analysis. The age and anthropometric characteristics of
the study participants are described in Table 1. Mean and
Fig. 1 Flow chart explaining the sample size reduction. RBC: Red Blood Cells, AT: Adipose Tissue
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reference values for plasma, RBC and AT α-tocopherol
concentrations by age-specific distribution are reported in
Table 2. No difference attributable to sex was found in this
study for α-tocopherol neither in plasma, RBC nor AT
(data non shown). Mean plasma concentrations decreased
slightly with age from 22.1 (children 1 month to 2 years)
to 19.8 μmol/L (children 12 to 18 years) (p < 0.05) as well
as mean AT α-tocopherol concentrations from 291 to
177 nmol/g (p < 0.01). RBC α-tocopherol concentrations
were not influenced by age ranging from 4.67 to 5.47 μmol/
L packed cells (p =NS) (Fig. 2).
Plasma α-tocopherol correlated significantly with total
cholesterol (r = 0.49, p < 0,001), LDLc (r = 0.42, p < 0,001)
and to a lesser value with RBC α-tocopherol (r = 0.31,
p < 0.01). Plasma and adipose α-tocopherol concentra-
tions correlated only in the group of children aged 12 to
18 years (r = 0.35, p < 0.1). No correlation was found in
this study between RBC and AT α-tocopherol (r = -0.02,
p = NS).
CMRD patients
As expected for individuals affected with CMRD, we
observed lower concentrations of total cholesterol, LDLc,
HDLc and Apo B in patients with CMRD compared with
control subjects (Table 1).
After the wash out of 2 months and before the 4-month
treatment period with α-tocopherol acetate, patients
showed decreased plasma (med = 5.8 ± 3.7 μmol/L) and
RBC (med = 2.1 ± 1.9 μmol/L packed cells) α-tocopherol
concentrations. The median AT α-tocopherol concen-
tration was 276 ± 227 nmol/g, close to the concentration
found in healthy control children.
After the 4 month-treatment period, the median α-
tocopherol concentration increased from 5.8 ± 3.7 to
14.1 ± 3.4 μmol/L in plasma but remained less than 70 %
of the mean observed in the controls. However, RBC
α-tocopherol increased by 180 % up to 5.9 ± 1.4 μmol/L
packed cells in RBC close to the mean observed in controls.
The median AT α-tocopherol concentration remained
stable and normal at 266 ± 217 nmol/g (Fig. 3).
Discussion
Only a few studies about antioxidant vitamins status
for children have been carried out in the last decade in
Table 1 Physical and biochemical parameters of included healthy children and patients with Chylomicron Retention Disease (CMRD)
Healthy children CMRD
0 - 2 years 2 - 12 years 12 - 18 years Total Total
n 56 75 35 166 4
Sex (F/M) 24/32 32/43 17/18 73/93 3/1
Age (y) 1.2 ± 0.6 5.9 ± 2.9 14.9 ± 1.7 6.2 ± 5.4 19 ± 2.8
Weight (kg) 9.5 ± 2.9 21.7 ± 9.1 55.3 ± 15.4 24.7 ± 19.3 54.0 ± 11.2
Height (cm) 74.7 ± 11.3 114.1 ± 19.0 163.0 ± 12.1 111.6 ± 35.4 160 ± 9.9
BMI (kg/m2) 16.85 ± 2.0 16.01 ± 1.9 20.4 ± 4.2 17.23 ± 3.1 20.2 ± 3.6
Total cholesterol (mmol/L) 3.74 ± 0.8 3.98 ± 0.8 3.95 ± 0.6 3.93 ± 0.7 2.31 ± 0.8
HDL cholesterol (mmol/L) 1.20 ± 0.5 1.31 ± 0.3 1.27 ± 0.2 1.28 ± 0.4 0.5 ± 0.1
LDL cholesterol (mmol/L) 2.24 ± 0.6 2.39 ± 0.6 2.28 ± 0.5 2.33 ± 0.6 1.50 ± 0.7
Triglycerides (mmol/L) 0.82 ± 0.5 0.63 ± 0.4 0.90 ± 0.5 0.74 ± 0.4 0.68 ± 0.3
Apolipoprotein B (g/L) 0.68 ± 0.2 0.66 ± 0.5 0.63 ± 0.1 0.65 ± 0.2 0.37 ± 0.2
Results as expressed as mean ± standard deviation
Table 2 Age-partitioned pediatric reference intervals for vitamin
E in plasma, red blood cells (RBC) and adipose tissue
Test Age
(years)






0 - 2 48 22.1 11.8 34.2
2 - 12 73 20 11.9 30.2
12 - 18 35 19.8 11.6 27.6
0 - 18 156 20.6 11.9 30
α-tocopherol/
cholesterol ratio
0 - 18 113 5.27 3.3 7.1
α-tocopherol/
triglycerides ratio
0 - 18 113 33.3 9.6 55.3
RBC α-tocopherol
(μmol/L packed cells)
0 - 2 30 5.47 2.5 9.9
2 - 12 37 4.67 1.7 7.8
12 - 18 28 5.12 2.6 9.8
0 - 18 95 4.96 2 7.8
Adipose tissue
α-tocopherol (nmol/g)
0 - 2 48 291 37 597
2 - 12 64 267 61 596
12 - 18 32 177 58 344
0 - 18 144 258 60 573
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Fig. 2 Box plot representation of α-tocopherol concentrations according to the age. Concentrations of vitamin E in a plasma, b red blood cells (RBC),
c adipose tissue (AT). The line in the middle of the box is plotted at the median. The boxs represent from the 25th to 75th percentiles. The whiskers




Fig. 3 Evolution of vitamin E concentrations after 4 months treatment with α-tocopherol acetate in patients with CMRD. Concentrations of vitamin E
in a plasma, b red blood cells (RBC), c adipose tissue (AT) after 4 months treatment with α-tocopherol acetate (50 mg/kg/d). CMRD : Chylomicron
Retention Disease. Results are expressed as median with interquartile range. The horizontal line with the dotted lines represents the mean observed
in healthy children
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European countries and no data are available to our know-
ledge on the reference values of α-tocopherol in RBC and
AT in American and European children. For the first time,
this study i) establishes current reference intervals in
children for the distribution of α-tocopherol in plasma,
RBC and AT and provides information on the distribution
of these variables by age in a cohort of French children
from 1 month to 18 years ii) reports data on the concen-
tration of vitamin E in CMRD patients in RBC and AT
and their evolution during treatment.
Plasma concentrations in healthy children/adolescents
and in CMRD patients
In this prospective study of 166 healthy children, we
reported mean plasma tocopherol concentrations and
reference values very close to those observed previously
in pediatric populations (Table 3) [13, 20, 21]. However,
very few studies published reference intervals for very
young children (<2 years old). Recently, Raizman et al.
also reported that vitamin E levels rose within the first
year of life and observed the widest interval within the
first year of life assuming that the broad ranges could
reflect changes over different gestational ages [14]. Values
reported in adults were different than those in children, as
shown by the SU.VI.MAX study, which reported mean
α-tocopherol concentrations close to 31 μmol/L in a cohort
of 12,741 French volunteers aged 35 to > 60 years [22].
Vitamin E is transported in circulation by plasma lipo-
proteins mainly LDL and HDL [23, 24]. Mean cholesterol
values reported in this study were closed to those reported
in European children and adolescents in the HELENA and
IDEFICS studies [25, 26] and slightly lower than those re-
ported among French children [27–29]. Since α-tocopherol
is known to increase with the degree of hyperlipidemia and
is dependent on lipid metabolism for delivery to tissues,
adjustment for total cholesterol or lipids is also important
to assess vitamin E status in some special conditions such
as cholestasis or cystic fibrosis [24, 30]. The observed vita-
min E/lipid ratios observed in this study are in agreement
with previous findings [14, 24, 31].
In CMRD patients, we confirmed that, even they were
treated with α-tocopherol acetate 50 mg/kg/d, plasma
α-tocopherol concentrations remained decreased because
its absorption is impaired and lipoprotein transport path-
ways are saturated. Even if the α-tocopherol/cholesterol
ratio reached normal values at the end of treatment, this
ratio does not seem to be ideal since α-tocopherol and
Table 3 Table summarizing our data and those obtained in previous studies
Our study Studies in children Studies in adults
Plasma α-tocopherol 0 - 2 yr (n = 48): 22.1 μmol/L 0 - <1 yr canadian children (n = 85):
5 - 50 μmol/L [14]
35 - 45 yr french females (n = 2163):
29.8 ± 6.7 μmol/L [22]
35 - 45 yr french males (n = 138):
31.9 ± 5.5 μmol/L [22]
1 - <19 yr canadian children (n = 245):
14.5 - 33 μmol/L [14]
45 - 50 yr french females (n = 1499):
31.0 ± 6.6 μmol/L [22]
45 - 50 yr old french males (n = 1379):
31.3 ± 6.7 μmol/L [22]
2 - 12 yr (n = 73): 20 μmol/L 10 - 15 yr french males and females
(n = 263 and 246): ≈ 20 and 21 μmol/L [20]
50 - 60 yr old french females (n = 1645):
31.5 ± 7.2 μmol/L [22]
50 - 60 yr old french males (n = 1919):
32.5 ± 7.4 μmol/L [22]
12 - 18 yr (n = 35):
19.8 μmol/L
12.5 - 17.49 yr european adolescents
(n = 1053): 23 μmol/L [21]
> 60 yr french females (n = 127):
33.2 ± 7.5 μmol/L [22]
> 60 yr french males (n = 159):
32.7 ± 9.3 μmol/L [22]
RBC α-tocopherol 0 - 2 yr: 5.47 μmol/L
packed cells
3 - 6 yr : 4.65 μmol/L packed cells [33] 4.09 μmol/L packed cells [33]
2 - 12 yr: 4.67 μmol/L
packed cells
7 - 10 yr : 4.07 μmol/L packed cells [33] 5.1 μmol/L packed cells [35]
12 - 18 yr: 5.12 μmol/L
packed cells
11 yr: 4.09 μmol/L packed cells [33] 18.5 nmol/g Hb (≈ 6.60 μmol/L packed
cells if Hb = 150 g/L and haematocrit 0.42) [34]
Adipose tissue α-
tocopherol
0 - 2 yr: 291 nmol/g AT None 192 μg/g fatty acids (≈ 292 nmol/g AT) [12]
2 - 12 yr: 267 nmol/g AT 190 nmol/g AT in 347 males and 286 nmol/g
in 111 females [11]
12 - 18 yr: 177 nmol/g AT 199 nmol/g AT [10]
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cholesterol remain both lower than normal values. It is
therefore an inaccurate “normal value” since the capacity
to transport adequate quantity of vitamin E to tissues
remains impaired [32].
RBC concentrations in healthy children/adolescents and in
CMRD patients
Our results regarding RBC α-tocopherol are consistent
with those previously described, although concentrations
cannot simply be compared to other studies because these
concentrations can be expressed in different ways. To our
knowledge, a single Japanese study reported references
values in children. Their data are in agreement with ours
as they reported that the mean RBC tocopherol was
179 μg/100 mL packed cells, ranging from 79 to 320 μg/
100 ml (corresponding to 4.16 μmol/L packed cells, range
1.84 – 7.41 μmol/L) in their 261 apparently healthy chil-
dren aged 3 to 16 years old (For concentrations detailed
by age, see Table 3) [33].
The concentration of vitamin E in RBC in adults seems
to be equivalent to concentrations in children, given that
RBC tocopherol was : i) 4.09 μmol/L packed cells in 26
adult controls aged between 20 and 33 years old in the
study about Japanese children [33] ii) 18.5 nmol/g Hb
(corresponding to 6.59 μmol/L packed cells if Hb = 150 g/L
and haematocrit 0.42) in a control population of 67 healthy
adults [34] iii) 5.1 μmol/L packed cells in a population of
20 healthy adults not supplemented [35].
In CMRD patients, the vitamin E in RBC was decreased
to about half of the normal value defined in the study after
2 months of wash out but increased to a normal value
after 4 months of supplementation. These results are
consistent with the half-life of erythrocytes of ≈ 120 days
and with results found by others in patients with genetic
hypocholesterolemia : i) Bieri et al. reported normal con-
centrations of α-tocopherol in RBC in two abetalipopro-
teinemia patients that were administered 750 mg aqueous
d-α-tocopherolyl succinate daily for several months [36]
and ii) Hatam et al. reported on a single supplemented
abetalipoproteinemia patient with RBC α-tocopherol con-
centrations ten times higher than a subject not taking
supplemental vitamin E (although the RBC concentration
was less than seen in normal subjects) [37]. Similarly,
Clarke et al. observed that normal RBC α-tocopherol
concentrations were noted in 2 homozygous hypobetali-
poproteinemia patients receiving supplementation, whereas
they remained low in one patient with ABL even if he was
supplemented [38].
AT concentrations in healthy children/adolescents and in
CMRD patients
Since vitamin E is a fat-soluble compound stored in AT,
concentrations in AT may be a better indicator of long
term intake than plasma levels. One objective of this work
was to establish reference values for α-tocopherol in AT
in healthy children. We found that adipose α-tocopherol
concentrations in children (258 ± 146 nmol/g, n = 144)
were similar to those described in adults.
In adults, the concentration of α-tocopherol in AT was
i) 192 μg/g fatty acids (corresponding to approximately
292 nmol/g of adipose tissue) in 727 healthy controls
enrolled in the EURAMIC study [12] and ii) 190 nmol/g
in 347 male and 286 nmol/g in 111 female controls [11].
Traber et al. who studied the effect of thermal injury on
body stores of vitamin E in pediatric patients (n = 8,
mean age = 15 years) showed that the AT α-tocopherol
concentrations in the initial biopsy within the first week
after injury were 199 nmol/g and reported that the
normal range observed in healthy adults was 200 to
700 nmol/g [10]. Interestingly, as with plasma tocopherol,
adipose α-tocopherol concentrations were significantly
higher in very young children (<2 years old) than in older
children (>12 years).
Finally, our CMRD patients who have been treated by
the recommended daily dose of 50 mg/kg of tocopherol
acetate for many years, had normal adipose α-tocopherol
concentrations after 2 months of wash out and 4 months
of treatment. This is in agreement with findings that some
ABL patients on massive supplementation with vitamin
E did achieve normal concentrations of AT tocopherol
[8, 39] and illustrates that changes in AT are very slow.
Handelman et al. estimated that more than 2 years are
required for the α-tocopherol/γ-tocopherol ratio to reach a
new steady state after a change in α-tocopherol intake [40].
Correlations between α-tocopherol in plasma, RBC and AT
in healthy children
Informations on the relationship between plasma, RBC
and AT levels of α-tocopherol in the free-living human
population are very limited.
We found a weak correlation between plasma and RBC
α-tocopherol in children. This correlation coefficient was
a bit lower than those reported by Mino et al. (r = 0.59,
p < 0.001) [33] and Lehmann et al. (r < 0.40) [35] and
was not improved by adjusting for lipids.
In this work, the coefficient of correlation between
plasma and adipose α-tocopherol concentrations in the
group of children aged 12 to 18 years old (r = 0.32, p = 0.06)
was very close to those observed in adults by Kardinaal et
al. (r = 0.31, p < 0.01) from 85 healthy, non-smoking
volunteers aged 50–70 years in the Netherlands [41] and
El-Sohemy et al. (r = 0.27, p not specified) in a population
of 482 Costa Rican [11]. Su et al. also reported a weak
correlation (r = 0.39, p < 0.01) between plasma and AT α-
tocopherol concentrations in the control group of the
EURAMIC study [42]. Finally, in a study with a small
number of subjects (n = 20), Schäefer et al. showed that
total tocopherol in plasma correlated significantly with
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AT total tocopherol (r = 0.47, p < 0.05) and that the con-
tent of n-3 fatty acids in AT influenced AT vitamin E
negatively [43]. Taken together this indicates that adipose
α-tocopherol concentrations are also influenced by factors
other than α-tocopherol intake or blood concentrations
such as genetic differences, needs for rapid development
and growth, or overall dietary habits in children.
We failed to detect any correlation between AT and
RBC in healthy controls subjects. Those results are con-
sistent with the fact that AT α-tocopherol probably repre-
sents a long-term measure of α-tocopherol status whereas
RBC α-tocopherol reflect a shorter-term intake.
Conclusion
We established for the first time the reference values of
α-tocopherol in plasma, RBC and AT in children, from the
neonatal period to early adulthood. These values will be
useful to assess the vitamin E nutritional status of children
in epidemiological studies or in particular diseases, such as
primary hypocholesterolemia including CMRD, familial
hypobetalipoproteinemia and abetalipoproteinemia. Our
data suggest that RBC α-tocopherol is a relevant biomarker
to monitor children with chylomicron retention disease. It
appears to be an appropriate biomarker of deficiency and
effectiveness of treatment since it decreases rapidly and can
be normalized after 4 months of supplementation; It is less
influenced by lipids than plasma α-tocopherol. The biopsy
of AT could be used at diagnosis to assess the severity
of the vitamin E deficiency and periodically after a long
duration of vitamin E therapy to assess whether the treat-
ment is effective and achieves values close to normal.
However, AT biopsies are not useful for regular monito-
ring due to the very slow change of vitamin E concentra-
tions in AT.
Considering that platelet tocopherol concentrations are
not influenced by lipids [35], reference values in children
would have been relevant given that it is important to use
more than one biomarker for tocopherol to evaluate the
effectiveness of treatment in patients with severe hypocho-
lesterolemia. Moreover, it is not clearly established whether
increased oxidative stress is seen in genetic hypocholeste-
rolemia. The measurement of urinary F2-isoprostanes in
healthy children and CMRD patients would probably have
provided valuable information [44].
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